Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 10/20 | 0.93 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.93 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.93 |
| ▸ | SAT1 | P21673 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2839904 | 0.98 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL3652066 | 0.98 | GNAO1 (0.96) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL7328368 | 0.94 | GNAO1 (0.83) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL5963013 | 0.90 | GNAI3 (0.75) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL8135765 | 0.89 | GNAO1 (0.75) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL13772115 | 0.86 | GNAO1 (0.70) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL7766302 | 0.86 | GNAI3 (0.69) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL1678880 | 0.86 | GNAI3 (0.69) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL19414059 | 0.84 | GNAI3 (0.72) | GNAO1GNAI3GNAI1SAT1EPHX1 | |
| SCHEMBL1933069 | 0.84 | GNAI3 (0.72) | GNAO1GNAI3GNAI1SAT1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4194457-A1 | COMPOUND FOR TARGETING AND DEGRADING PROTEIN, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Leadingtac Pharmaceutical Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-105646331-B | Piperidine compounds, the medical composition and its use containing the compound | 爱思开生物制药株式会社 | 2018-07-03 | — | — | CN | disclosed |
| CN-103980184-B | Piperidine compounds, medical composition and its use containing this compound | 爱思开生物制药株式会社 | 2016-08-24 | — | — | CN | disclosed |
| US-20100298380-A1 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THIER USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-11-25 | — | — | US | disclosed |
| US-20100298380-A1 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THIER USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-11-25 | — | — | US | disclosed |
| EP-2183240-A2 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch AS (DK) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009016215-A3 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH AS (DK) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009016215-A2 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298380-A1 | N-ARYL-N-PIPERIDIN-4-YLMETHYL-AMIDE DERIVATIVES AND THIER USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A4 | GNAO1 1099/4885GNAI3 885/4885GNAI1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.